Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sanjay Popat

Showing results (191-200 of 273) with videos related to

Pageof 28
Sort By:
Frontiers in Medicine|November 18, 2021
Immune Checkpoint Inhibitor and Radiotherapy-Related Pneumonitis: An Informatics Approach to Determine Real-World Incidence, Severity, Management, and Resource ImplicationsSumeet Hindocha, Des Campbell, Merina Ahmed, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 16, 2024
Assessing the sensitivity and acceptability of the Royal Marsden Palliative Care Referral "Triggers" Tool for outpatients with cancerLaila Kamal, Yuki Kano, Anna-Marie Stevens, et al.
Cancer|April 16, 2013
Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patientsAndrew J Weickhardt, Robert C Doebele, W Thomas Purcell, et al.
Cardio-Oncology (London, England)|November 24, 2022
The spectrum of cardiovascular complications related to immune-checkpoint inhibitor treatment : Including myocarditis and the new entity of non inflammatory left ventricular dysfunctionMaria Sol Andres, Sivatharshini Ramalingam, Stuart D Rosen, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 4, 2026
Definitive Radiotherapy to the Primary Tumor in Stage IV NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer Advanced Radiation Technology SubcommitteeRyan A McMahon, Kevin Lee Min Chua, Corinne Faivre-Finn, et al.
The Journal of Pathology|September 27, 2024
Genomic analysis defines distinct pancreatic and neuronal subtypes of lung carcinoidClara Domingo-Sabugo, Saffron Ag Willis-Owen, Amit Mandal, et al.
The Oncologist|March 11, 2022
Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG)Sanjay Popat, Te-Chun Hsia, Jen-Yu Hung, et al.
Scientific Reports|June 15, 2021
Y disruption, autosomal hypomethylation and poor male lung cancer survivalSaffron A G Willis-Owen, Clara Domingo-Sabugo, Elizabeth Starren, et al.
British Journal of Cancer|December 5, 2024
Long term efficacy of first-line afatinib and the clinical utility of ctDNA monitoring in patients with suspected or confirmed EGFR mutant non-small cell lung cancer who were unsuitable for chemotherapySanjay Popat, Adam Januszewski, Mary O'Brien, et al.
Nature Reviews. Clinical Oncology|March 15, 2025
Utilizing ctDNA to discover mechanisms of resistance to targeted therapies in patients with metastatic NSCLC: towards more informative trialsSophie M Ernst, Mihaela Aldea, Jan H von der Thüsen, et al.
Pageof 28

Showing results (191-200 of 273) with videos related to

Sort By:
Pageof 28
Frontiers in Medicine|November 18, 2021
Immune Checkpoint Inhibitor and Radiotherapy-Related Pneumonitis: An Informatics Approach to Determine Real-World Incidence, Severity, Management, and Resource ImplicationsSumeet Hindocha, Des Campbell, Merina Ahmed, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 16, 2024
Assessing the sensitivity and acceptability of the Royal Marsden Palliative Care Referral "Triggers" Tool for outpatients with cancerLaila Kamal, Yuki Kano, Anna-Marie Stevens, et al.
Cancer|April 16, 2013
Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patientsAndrew J Weickhardt, Robert C Doebele, W Thomas Purcell, et al.
Cardio-Oncology (London, England)|November 24, 2022
The spectrum of cardiovascular complications related to immune-checkpoint inhibitor treatment : Including myocarditis and the new entity of non inflammatory left ventricular dysfunctionMaria Sol Andres, Sivatharshini Ramalingam, Stuart D Rosen, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 4, 2026
Definitive Radiotherapy to the Primary Tumor in Stage IV NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer Advanced Radiation Technology SubcommitteeRyan A McMahon, Kevin Lee Min Chua, Corinne Faivre-Finn, et al.
The Journal of Pathology|September 27, 2024
Genomic analysis defines distinct pancreatic and neuronal subtypes of lung carcinoidClara Domingo-Sabugo, Saffron Ag Willis-Owen, Amit Mandal, et al.
The Oncologist|March 11, 2022
Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG)Sanjay Popat, Te-Chun Hsia, Jen-Yu Hung, et al.
Scientific Reports|June 15, 2021
Y disruption, autosomal hypomethylation and poor male lung cancer survivalSaffron A G Willis-Owen, Clara Domingo-Sabugo, Elizabeth Starren, et al.
British Journal of Cancer|December 5, 2024
Long term efficacy of first-line afatinib and the clinical utility of ctDNA monitoring in patients with suspected or confirmed EGFR mutant non-small cell lung cancer who were unsuitable for chemotherapySanjay Popat, Adam Januszewski, Mary O'Brien, et al.
Nature Reviews. Clinical Oncology|March 15, 2025
Utilizing ctDNA to discover mechanisms of resistance to targeted therapies in patients with metastatic NSCLC: towards more informative trialsSophie M Ernst, Mihaela Aldea, Jan H von der Thüsen, et al.
Pageof 28